Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
NexIUM
(United States) [Available] ,Nexium 24hr
(United States) [Available]Synonyms :
esomeprazole
Class :
Drugs for peptic ulcer & Proton pump inhibitors
Brand Name :
NexIUM
(United States) [Available] ,Nexium 24hr
(United States) [Available]Synonyms :
esomeprazole
Class :
Drugs for peptic ulcer & Proton pump inhibitors
Indicated for NSAID-Induced Gastric Ulcer
Administer 20 mg orally every day for four to eight weeks
Administer 80 mg orally divided every twelve hours
Modify the treatment plan according to its effectiveness; administer orally up to 240 mg once a day or 120 mg orally divided every twelve hours is given to patients
when both drugs are combined, there may be a decrease in levels of serum concentration and absorption of erlotinib
it may decrease the serum concentration of bosutinib
may decrease the serum concentration
belumosudil: they may diminish the serum concentration of Inhibitors of the Proton Pump
may decrease the diagnostic effect of each other when combined
it may decrease the absorption of Levoketoconazole
may decrease the serum concentration
they decrease the concentration of active metabolites of infigratinib in the serum
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
When dexrabeprazole and esomeprazole is used together, this leads to reduction in the dexrabeprazole’s metabolism
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
When bacampicillin is combined with esomeprazole, bacampicillin absorption and blood levels decrease by stomach acid reduction.
when both drugs are combined, there may be an increased risk of hypomagnesemia
Proton Pump inhibitors may increase the absorption of amphetamine
it may decrease the serum concentration of Atazanavir
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may decrease the serum concentration of Multivitamins
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
may increase the serum concentration of itraconazole
they decrease the efficacy of cysteamine
This could lead to a reduction in concentration serum of mycophenolate
may have a decrease in excretion when combined with esomeprazole
it enhances the level of bismuth subsalicylate by increasing the gastrointestinal absorption
it enhances the effect of alprazolam by diminishing the metabolism
Actions and spectrum:
Actions:
The S-isomer of omeprazole is esomeprazole. It inhibits acid secretion by binding to the H+/K+ ATPase in gastric parietal cells.
Spectrum:
Esomeprazole is prescribed to treat H. pylori infection, GERD, Zollinger-Ellison syndrome, and peptic ulcer disease.
Frequency defined
1%-10%
Abdominal pain
Constipation
Diarrhea
Nausea
Dizziness
Headache
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Cautions:
Pregnancy/Lactation:
Pregnancy consideration: No adverse effects have been reported in animal reproduction studies. It can be recommended for the treatment of GERD in pregnant women. (maternal dose 10 mg/day)
Lactation: Esomeprazole can be excreted in breast milk, use with caution.
Pregnancy category:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
Esomeprazole is a proton pump inhibitor, it’s the S-isomer of omeprazole.
Pharmacodynamics:
Esomeprazole, a benzimidazole, inhibits acid secretion by blocking H+/K+ATPase.
Pharmacokinetics:
Absorption
Esomeprazole’s oral bioavailability is 89-90%.
Distribution
97% of the drug is known to be bound to proteins.
The volume of distribution is 16L.
Metabolism
The drug metabolism occurs in the liver.
Excretion and Elimination
80% of esomeprazole drug is excreted through urine, whereas 20% is eliminated through feces.
Administration:
Administer the capsule orally before food.
Intravenous administration should be carried over less than three minutes.
Patient information leaflet
Generic Name: esomeprazole
Pronounced: es-oh-MEP-ra-zole
Why do we use esomeprazole ?
Esomeprazole is a proton pump inhibitor (PPI) that works by reducing the amount of acid produced in the stomach. It is widely used to treat a variety of acid-related gastrointestinal conditions.
The primary use of esomeprazole is in the treatment of gastroesophageal reflux disease (GERD), where it helps relieve symptoms such as heartburn, regurgitation, and inflammation of the esophagus. It is also effective in healing erosive esophagitis caused by acid damage. Esomeprazole is used in the management of peptic ulcer disease, including both gastric and duodenal ulcers, and is often combined with antibiotics like amoxicillin and clarithromycin to eradicate Helicobacter pylori infection.
In addition, it is used for the prevention and treatment of NSAID-associated gastric ulcers in patients requiring long-term NSAID therapy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
